Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis. Issue 11 (November 2022)

• Record Type: Journal Article
• Authors: Trideva Sastri, K.; Vishal Gupta, N.; Kannan, Anbarasu; Balamuralidhara, V.; Ramkishan, A.
• Is Part Of: Drug discovery today. Volume 27:Issue 11(2022)
• Publication Date: 2022-11
• Subjects: Multiple sclerosis -- miRNA-based therapies -- Nanocarrier systems -- Recent studies; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2022.103357
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: Impact of miRNA in Multiple Sclerosis. Nanocarriers mediated miRNA delivery. Recent advances in miRNA - therapies for managing Multiple Sclerosis. Abstract : Multiple sclerosis (MS) is an autoimmune neuroinflammatory disorder attributed to neurodegeneration and demyelination, resulting in neurological impairment. miRNA has a significant role in biological processes in MS. In this review, we focus on the feasibility of delivering miRNAs through nanoformulations for managing MS. We provide a brief discussion of miRNA synthesis and evidence for miRNA dysregulation in MS. We also highlight formulation strategies and resulting technologies for the effective delivery of miRNAs through nanocarrier systems for achieving high therapeutic benefits.